ATLANTA (August 30, 2017) – Intent Solutions™, creator of the breakthrough medical device technology tad™, is excited to announce the addition of its new Chief Strategy Officer, Paul Quiner. Paul has spent his career in healthcare both from product and service perspectives. “Paul brings extensive experience in business including strategy, mergers and acquisitions experience,” said Sam Zamarripa, CEO. “In addition we believe that Paul’s legal training will give him a unique perspective on our regulatory issues at both the state and federal level.”
INTENT SOLUTIONS™ HIRES CHIEF OPERATING OFFICER Ward Broom Will Oversee Strategy to Bring TAD™ to the Commercial Market
ATLANTA (June 23, 2017) – Intent Solutions™, creator of the breakthrough medical device technology TAD™, is excited to announce the addition of its new Chief Operating Officer, Ward Broom. With a background of co-founding a healthcare business, Broom’s experience includes taking a product from development to an exit. Broom has two degrees from the Georgia Institute of Technology and is currently completing his MBA there with a focus in management of technology, getting up to speed with the latest practices in business management.
“I was originally drawn to the Intent Solutions team because of their leadership and passion for the product,” said Broom. “TAD is poised for commercialization, and I enjoy the start up community and challenges that it presents. The idea of taking another healthcare product that has the potential to benefit the community and medical research field and helping to commercialize and make it a reality is very exciting.”
TAD, for “Take As Directed,” is a smart, mobile, medication dispenser that helps patients obtain better health outcomes by helping the right patient take the right dose at the right time.
At Intent Solutions, Broom will develop the operational strategies for the organization as it gains customers and ramps up for growth. Focusing on the internal processes including customer interfacing, implementations, and product management, Broom will be an asset for Intent Solutions as it moves forward into a new phase of growth.
For more information, visit www.IntentSolutions.com
or contact firstname.lastname@example.org
Last week we had a great opportunity to interview Jacob Levenson, CEO of Map Health Management, of Austin, Texas. We focused our conversation on the importance of technology and data in population health---understanding where we are coming from and where we’re are going with this sea of data!
Going to HIMSS '17 in Orlando? On Monday February 20th, Tyler McCrary will be at MAP Health Management's booth, 6744. Come by to see a demonstration of TAD and hear about our partnership with MAP Health.
ANNOUNCEMENT: MAP Announces Partnership with Intent Solutions to Assess Medication Compliance in Patients with Addiction
MAP ANNOUNCES PARTNERSHIP WITH INTENT SOLUTIONS TO ASSESS MEDICATION COMPLIANCE IN PATIENTS WITH ADDICTION
MAP Health Management, LLC., announced today a partnership with Intent Solutions designed to track adherence to medication protocols for patients with a Substance Use Disorder diagnosis who are served by MAP’s patient engagement technology. Intent Solutions is the creator of the TAD™, a biometric pill dispensation device that can track in real-time who has or has not taken their medication.
The partnership will launch with a pilot program as early as March of this year wherein a number of patients whose risk for relapse is continuously measured by MAP’s technology will be provided a TAD™ device. The device will send real-time data to MAP’s platform when a patient takes their medication, or fails to do so. With this information, MAP can inform the appropriate members of collaborative care networks if a patient is overusing their medication, or failing to take their medication at all. This information is then leveraged to improve clinical outcomes and manage financial risk through facilitating early interventions and other modes of mitigating recidivism and costly treatment episodes.
INTENT SOLUTIONS™ ANNOUNCES NEW ADVISORY BOARD MEMBER
David R. Gastfriend, M.D. to Bring Pharma-Tech Knowledge
ATLANTA (January 17, 2017) – Intent Solutions™, creator of the breakthrough medical device technology TAD™, is excited to announce the appointment of David R. Gastfriend, M.D., chief architect of CONTINUUM, the American Society of Addiction Medicine’s standardized treatment software, to its Advisory Board. Gastfriend brings a vast wealth of pharma-tech experience from his work at Alkermes, Inc., where he supported gaining FDA approval of VIVITROL® for the treatment of alcohol and opioid dependence. Most recently, Gastfriend co-founded DynamiCare Health, Inc., a technology start-up that focuses on incentivizing patients for compliance on treatments. As a clinical scientist in addiction, he will assist in helping Intent Solutions optimize TAD for improving patient adherence, as well as advise the company on leveraging the various stakeholders in the healthcare system to achieve change and improvements in patient outcomes.
Clinical Trials Insight: "Adherence Data Gets Smart"
The very definition of is on the brink of change because of new technologies, sensors and real-time data. Intent Solutions is a part of a major shift in the digital health economy where the ability to monitor and stream vast sets of new, real-time data in clinical research and health delivery will reveal how and when people take medications.
Intent Solutions Looks to Expand Market
DECEMBER 6, 2016 BY KATHY DION
ATLANTA – With $1.5 million in new funding on the books, Intent Solutions aims to expand the market for its TAD smart medication dispenser technology.
TAD has been attracting attention from big specialty pharmaceutical companies recently and Sam Zamarripa, president/director of Intent Solutions, hopes to work with them on clinical research to expand the market for the device.
INTENT SOLUTIONS™ RAISES $1.5 MILLION IN SEED CAPITAL
Announces first equity round of financing to drive growth in 2017
ATLANTA (November 11, 2016) – Intent Solutions™, creator of the breakthrough medical device technology TAD™, announced today that is has successfully completed a seed round of funding of $1.5 million.
TAD, for “Take As Directed,” is a smart, mobile, medication dispenser that helps patients obtain better health outcomes by helping the right patient take the right dose at the right time. TAD, which can be programmed to a specific regimen and schedule, incorporates biometric access and is fully tamper resistant. The medication dispenser also records adherence data, which is sent to a cloud database for analysis, reducing errors and simplifying data reconciliation for clinical trials.
Intent Solutions raises $1.5M for connected device aimed at medication adherence, abuse prevention
By Jonah Comstock | November 14, 2016
Intent Solutions, an Atlanta-based company working on a connected medication dispenser called TAD, has raised $1.5 million in seed funding. The company did not disclose the investors.
INTENT SOLUTIONS™ ANNOUNCES NEW ADVISORY BOARD MEMBER
Chris Hassan to Bring Vast Patient Care and Treatment Knowledge
ATLANTA (October 19, 2016) – Intent Solutions™, creator of the breakthrough medical device technology TAD™, is excited to announce the appointment of Chris Hassan, previous CEO at Colonial Management Group, LP, to its Advisory Board. Hassan brings a vast wealth of knowledge from his years overseeing the treatment and medication of tens of thousands of patients with opioid use disorder at Colonial Management Group, LP. Moreover, Hassan has been on the front edge of drug development for major pharmaceuticals including Depot Naltrexone, as well as the commercial introduction of Buprenorphine in the US, which is now the standard of care in office based opioid treatment. As an expert on drug abuse science, he will advise Intent Solutions on issues including TADs ability to help treat opioid use disorder.
INTENT SOLUTIONS™ ANNOUNCES NEW ADVISORY BOARD MEMBER
Barbara Tardiff to Bring Clinical Practice and Research Operations Knowledge
ATLANTA (November 4, 2016) – Intent Solutions™, creator of the breakthrough medical device technology TAD™, is excited to announce the appointment of Barbara Tardiff, M.D., former vice president, development operations, worldwide head, clinical informatics and innovation at Pfizer, to its Advisory Board. Dr. Tardiff brings a wealth of knowledge from her two decades of clinical practice and experience as a clinical investigator. Over the course of her career she has participated in a broad range of scientific and operational activities related to medical product development, including protocol design, data management, information systems, and interpretation and presentation of study findings. Dr. Tardiff has extensive operational experience in conducting clinical research in collaboration with many of the world’s major pharmaceutical firms. She will advise Intent Solutions on issues including product features and capabilities to ensure it addresses drug development and clinical practice needs.
"Adherence to medication is vital to the accuracy of clinical trials, but reporting missed pills is often left to patients. Now, a smart portable drug dispenser has been developed that not only prompts timely administration, but also feeds back to doctors and trial managers as to when and why the regimen was disrupted. Clinical Trials Insight speaks to the president of Intent Solutions, Sam Zamarripa, to find out more." - Clinical Trials Insight (Vol. 1, Issue 2016)
ATLANTA, GA–(Marketwired – October 26, 2015) – On October 16, 2015, Health Connect South Radio welcomed to the studio Lou Malice and Sam Zamarippa with Intent Solutions, and Tommy Cunningham with NFANT Labs. Host CW Hall led a roundtable discussion with these two Atlanta area health technology companies.
Intent Solutions is a start-up that is developing a device aimed at improving compliance with prescribed medication regimens, as well as helping to improve the likelihood the intended person has access to the medicine. In its early phase of development, Intent Solutions has positioned itself to be an effective tool for pharmaceutical research studies. In these studies, it is vital that participants adhere to the prescribed medication regimen in order to obtain the most effective and accurate test results.
"The Future of Rx Bottles; End of Opioid Crisis?
What if a patient could only access their pills during the time their doctor directed, and received only the exact dosage? The device, TAD, “take as directed” is looking to put a tighter cap on prescription abuse.
The pill bottle of the future, developed by Intent Solutions, pictured left, houses a portable dispenser that contains a disposable vial attached to a pre-programmed reusable electronic device, according to a Palm Beach Post report..."
Click to view TAD image displayed in Times Square
American Pharmacists Association
Intent Solutions introduced a mobile medication dispenser at the recent National Rx Drug Abuse and Heroin Summit. TAD, or "Take As Directed," was developed to stop overdoses, thwart illegal prescription drug sales, and help patients remember to take their medications.
Fingerprint recognition, locks could be coming to pill bottlesATLANTA — Imagine a prescription drug bottle that only can dispense your medication at the exact time you should take it, in the proper amount and only after it scans your fingerprint and confirms your identity.
New Device Combines Patient Biometrics, Cloud Data Analytics and Patented Safety Measures to Improve Opioid Adherence and Deter Abuse
ATLANTA (March 28, 2016) – A pioneering breakthrough in medical device technology called TAD™, for “Take As Directed,” will be introduced at this month’s National Rx Drug Abuse and Heroin Summit March 28 – 31. The availability of TAD™ to the prescription marketplace brings technological innovation into the ongoing policy discussions surrounding opioid adherence and abuse prevention, as the device successfully eliminates access to all medications at once while at the same time barring access to the medication by anyone other than the patient to whom it was prescribed.
Staff Writer - Atlanta Business Chronicle
March 28th, 2016
Prescription drug abuse recently surpassed auto accidents as the No. 1 cause of injury related deaths in the United States, and a company led by prominent former Georgia State Sen. Sam Zamarripa believes it has a device that can help.
Atlanta-based Intent Solutions' medical device TAD, which stands for "Take As Directed," eliminates access to all of a patient's medications at once while barring access to anyone besides the patient.